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Most of HIV-1 infections are acquired through sexual contact. In the absence of a preventive vaccine, the development of topical
microbicides that can block infection at the mucosal tissues is needed. Dermaseptin S4 (DS4) is an antimicrobial peptide derived from
amphibian skin, which displays a broad spectrum of activity against bacteria, yeast, filamentous fungi, and herpes simplex virus type 1. We
show here that DS4 inhibits cell-free and cell-associated HIV-1 infection of P4-CCR5 indicator cells and human primary T lymphocytes. The
peptide is effective against R5 and X4 primary isolates and laboratory-adapted strains of HIV-1. Its activity is directed against HIV-1 particles
by disrupting the virion integrity. Increasing the number of DS4-positive charges reduced cytotoxicity without affecting the antiviral activity.
The modified DS4 inhibited HIV-1 capture by dendritic cells and subsequent transmission to CD4+ T cells, as well as HIV-1 binding on HEC-
1 endometrial cells and transcytosis through a tight epithelial monolayer.
D 2005 Elsevier Inc. All rights reserved.
Keywords: Dermaseptin S4; Microbicide; Herpes simplex virus type 1Introduction
The predominant mode of human immunodeficiency
virus type 1 (HIV-1) transmission worldwide is via hetero-
sexual contact, with a higher rate of transmission to females
than to males (UNAIDS, 2002). For sexual transmission to
occur, infectious HIV-1 must cross the mucosal epithelium.
Epithelial cells in genital and gastrointestinal tracts do not
express CD4, but HIV-1 can bind to the cell membrane using
a galactosyl-ceramide (Bomsel and Alfsen, 2003). HIV-1
could cross the pluristratified squamous epithelium of the
vagina, exocervix or anus by physical breaches, or after
capture or infection of dendritic cells (DCs). The transfer of
HIV-1 across the monostratified epithelium of the endocer-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.vix, rectum, or gastrointestinal tract can occur by trans-
cytosis, binding on Langerhans cells or infection of the
intraepithelial lymphocytes (Bomsel, 1997; Bomsel and
Alfsen, 2003; Pope and Haase, 2003; Stone, 2002). After
crossing the epithelial barrier, HIV-1 can infect CCR5-
expressing DCs, macrophages and T lymphocytes in the
submucosa (Geijtenbeek et al., 2000; Greenhead et al., 2000;
Spira et al., 1996), then spread to circulating CD4+ T cells.
Since most new infections occur in developing countries,
new methods of HIV prevention that can be controlled by
women are urgently needed. These methods include the use
of topical microbicides able to prevent HIV-1 entry through
mucosa. Topical HIV-1 inhibitors may target the incoming
virus at several steps of molecular events that drive viral entry
(Eckert and Kim, 2001; Wyatt et al., 1998). They may also
target specifically submucosal cells to prevent infection (Hu
et al., 2004; O’Hara and Olson, 2002; Pierson and Doms,
2003; Reimann et al., 2002; Shattock and Moore, 2003).05) 264–275
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the binding of gp120 to CD4 or co-receptor (Bewley, 2001;
Chang et al., 2003; Moulard et al., 2000; Poignard et al.,
2001) or the fusion stage (Kilby et al., 1998). HIV-1
membrane is fragile and prone to disruption by many
chemical agents. However, viral membrane is derived from
the host cells from which it buds. Thus, the cytotoxicity of
drugs that target viral membrane has to be evaluated on
epithelial cells (Van Damme et al., 2002). Sexually trans-
mitted diseases (STDs) have a marked effect on both viral
shedding in the genital tract and the risk of acquiring HIV-1
infection, since they increase inflammation and create lesions
in the vaginal or rectal tissues (Kovacs et al., 2001). Hence, an
ideal microbicide should protect not only against HIV-1 but
also against genital herpes and common bacterial infections.
Dermaseptin S4 (DS4) is a 28-residue antimicrobial
peptide isolated from frog skin (Mor et al., 1991, 1994).
This linear cationic peptide adopts an amphipathic a-helical
conformation upon association with lipid bilayers, leading to
membrane permeabilization and microbe death. Selective
membrane recognition is related to the lipid composition of
the target membrane and its electrical potential (Gaidukov et
al., 2003; Kustanovich et al., 2002). DS4 displays a broad
spectrum of activity affecting Gram-negative and Gram-
positive bacteria, yeast, filamentous fungi, Plasmodium
falciparum, and the enveloped herpes simplex virus type 1
(HSV-1) (Belaid et al., 2002; Efron et al., 2002; Mor et al.,
1994). Increasing the positive charge and reducing the
hydrophobicity of the native peptide have been shown to
correlate with selective antimicrobial activity and reduced
toxicity in mammalian cells (Kustanovich et al., 2002).
In this study, we investigated the antiviral effect of DS4
against HIV-1 in vitro. The ability of DS4 to reduce cell-
free or cell-associated HIV-1 transmission was evaluated
on different target cells: P4-CCR5 indicator cells, human
primary T lymphocytes, and monocyte-derived dendritic
cells (DCs). We also investigated the capacity of DS4 to
impair HIV-1 attachment to human epithelial cells and
DCs, as well as transcytosis through a tight epithelial
barrier. The effect of the peptide on the viral particle was
explored, and to pre-clinically test DS4 as a potential
topical microbicide, we established the levels of efficacy
versus toxicity.Fig. 1. Effect of dermaseptins S4 and K4-S4 on HIV-1LAI infection and
cytotoxicity. P4-CCR5 cells were subjected to a 2-h infection with HIV-
1LAI in presence of the indicated concentration of the different forms of
dermaseptin S4. h-Galactosidase production was quantified 48 h post-
infection (solid lines). Cytotoxicity was quantified by trypan blue exclusion
following a 24-h exposure on P4-CCR5 cells (dashed lines).Results
Dermaseptin S4 inhibits HIV-1 infection of P4-CCR5
indicator cells
The antiviral effect of DS4 was first evaluated using a
single cycle virus infectivity assay on P4-CCR5 indicator
cells (Lorin et al., 2004). These cells express the CD4,
CCR5, and CXCR4 HIV-1 receptors and are stably trans-
fected with LacZ, inducible by HIV Tat. Therefore, they are
susceptible to HIV-1 isolates and express h-galactosidaseupon infection. P4-CCR5 cells were infected with HIV-1LAI
in presence of increasing concentrations of DS4 (0.35–
11.2 AM). Fig. 1 shows that DS4 inhibited HIV-1 infection
of reporter target cells in a dose-dependent manner. More
than 90% reduction of infection was observed in presence of
3.5 AM DS4 and 50% reduction in presence of 1.5 AM.
P4-CCR5 cells viability was determined after 24-h exposure
to increasing concentrations of DS4. Fig. 1 shows that cells
remained viable in the presence of DS4 concentrations that
inhibited 90% of HIV-1 infection. However, DS4 concen-
trations higher than 5 AMwere significantly cytotoxic in this
assay. For this reason, we modified DS4 peptide with the
aim to reduce its toxicity without affecting its antiviral
activity.
Biochemical modifications reduce DS4 cytotoxicity
It has been previously shown that increasing the net-
positive charge and reducing the hydrophobicity of DS4
resulted in reduced hemolytic activity and high antibacterial
activity (Efron et al., 2002; Feder et al., 2000; Kustanovich
et al., 2002). In the present study, DS4 analogs were
synthesized by introducing deletions, substitutions, or both
in the native 28-aminoacid sequence of DS4 (Table 1). Both
antiviral activity and cytotoxicity of these analogs were
evaluated using P4-CCR5 target cells. Peptide concentra-
tions causing 50% inhibition of HIV-1 infectivity (IC50) and
concentrations causing 50% cytotoxicity (CC50) after 24 h
of exposure were measured. The selectivity index (SI), the
ratio CC50/IC50, was calculated and results for all analogs
are summarized in Table 1. The C-terminal amidation of
native DS4 had no significant effect on the peptide toxicity
for P4-CCR5 cells or on its anti-HIV-1 activity. Deletions
of the C-terminal region dramatically affected the anti-HIV-
1 activity: DS4-(1–16)a was 5-fold less active than the
native peptide, and DS4-(1–12)a or DS4-(1–9)a were
inefficient, even at a concentration of 100 AM. Likewise,
Table 1
Selectivity index of DS4 derivatives
Peptide Sequence IC50
a CC50
b SIc
S4 ALWMTLLKKVLKAAAKAALNAVLVGANA 2 4.5 2.25
S4a –––––––––––––––––––––––––––––––––––––––NH2 2 5.6 2.8
K4-S4 ––––K––––––––––––––––––––––––––––––––– NH2 1.4 16.8 12
S4-(1–16)a —————————–—–NH2 N19.2 19.2 1
K4-S4-(1–16)a ––––K–––––––––––––––––NH2 28 N100 N3.6
S4-(1–12)a —————————NH2 N100 N100 1
S4-(1–9)a ———————NH2 N100 N100 1
S4-(6–28) ————————————————— N100 N100 1
a Peptide concentration (AM) that induces 50% infection inhibition on P4-CCR5 cells by HIV-1LAI.
b Peptide concentration (AM) that causes 50% cytotoxicity on P4-CCR5 cells.
c Selectivity index: ratio CC50/IC50.
Fig. 2. Spectrum of anti-HIV activity of dermaseptin K4-S4. (A) The
percentage of infection of P4-CCR5 cells by HIV-1 primary isolates (Bx08,
US714, US660, HT593, NDK, JR-CSF (clade B), 2553 (clade A)) or
laboratory-adapted strain LAI in presence of 3.5 AM K4-S4 is presented.
The 100% of infection for each virus was determined in absence of K4-S4.
Cells were washed 24 h post-infection and h-galactosidase production was
quantified 48 h post-infection (error bars indicate standard deviation). (B)
CEM cells were infected with HIV-1LAI and then co-cultivated with P4-
CCR5 cells in absence or presence of K4-S4 (3.5 AM). h-Galactosidase
activity was measured in P4-CCR5 cells 48 h post-coculture.
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tide but weakened its anti-HIV-1 activity (DS4-(6–28) was
10-fold less active). On the contrary, a positive charge mo-
nosubstitution without shortening the length of the peptide
(Met Y Lys in position 4) reduced the cytotoxicity but did
not affect the anti-HIV-1 activity. Dermaseptin K4-S4 has
the highest selectivity index among all analogs tested.
Taken together, these results show that making shorter DS4
abolishes its cytotoxicity but reduces its anti-HIV-1 activity,
and that a positive charge substitution in dermaseptin K4-S4
reduces the cytotoxicity without affecting the anti-HIV-1
activity. All further experiments on P4-CCR5 cells were
performed with dermaseptin K4-S4 at non-toxic concen-
trations lower than 3.5 AM.
Dermaseptin K4-S4 is active against X4 and R5 HIV-1
We examined the spectrum of activity of dermaseptin
K4-S4. Fig. 2A shows that dermaseptin K4-S4 is active
against a broad spectrum of HIV-1 viruses: the infectivity of
the laboratory adapted LAI strain as well as several primary
clade B or A and X4- or R5-tropic isolates (Bx08, US660,
US714, HT 593, 3253, NDK, JR-CSF) were inhibited. This
observation is consistent with a compound, which interacts
rather with the plasma membrane phospholipids than with
proteins (Strahilevitz et al., 1994). Fig. 2B shows that
dermaseptin K4-S4 also reduced the transmission of HIV-
1LAI from infected CEM cells to P4-CCR5 cells. This result
indicates that the peptide is able to inhibit cell-associated
virus infection as well. However, we cannot exclude that in
this experiment dermaseptin inhibited also free particles
newly produced by infected T cells.
Dermaseptin K4-S4 is active before or at viral entry
To determine which part of HIV-1 life cycle is inhibited,
we introduced the peptide at different stages in single
cycle infection experiments. Infections were performed on
P4-CCR5 cells, with constant doses of both HIV-1LAI (1 ng
p24) and dermaseptin K4-S4 (3.5 AM). Fig. 3A shows that
dermaseptin K4-S4 was active only when added before or
present at the time of infection. When the peptide was added
1-h post-infection, no activity was observed. This suggeststhat dermaseptin K4-S4 acts either directly on viral particles
or at the virus-cell interface before or at the moment of
attachment and/or entry. Pre-treatment of P4-CCR5 cells
with the peptide, followed by washing prior to infection
with HIV-1LAI, had no effect on infectivity (Fig. 3A). In
contrast, cell-free incubation of HIV-1LAI with 3.5 AM
dermaseptin K4-S4 before infection resulted in a strong
reduction of infectivity (Fig. 3B).
Fig. 3. Mechanism of anti-HIV activity of dermaseptin K4-S4. (A) K4-S4 (3.5 AM) was added at different time to P4-CCR5 cells infected with HIV-1LAI. Cells
were pre-incubated with the peptide 10 min at 37 8C, washed or not washed, and then submitted to 2-h infection. Alternatively, the peptide was added during
viral entry or 1 h post-entry. Viral replication was monitored by measuring h-galactosidase in cells, 48 h post-infection. Results are means of two independent
experiments performed in duplicate. (B) HIV-1LAI was pre-incubated at 37 8C alone or in presence of K4-S4 (3.5 AM) for different times and the remaining
infectivity was evaluated on P4-CCR5. Cells were submitted to a 2-h infection by pre-treated virus and h-galactosidase was measured 48 h post-infection.
Results are means of two independent experiments performed in duplicate (error bars indicate standard deviation). (C) P4-CCR5 cells were incubated for
10 min at 37 8C with fluoresceinated peptide (3.5 AM), washed, and observed under a confocal microscope (magnification x30). (D) Equal amounts of HIV-
1NL43 (100 ng p24) treated with NP40 1% or K4-S4 (0.35-35 AM) were ultra-centrifuged. Pelleted material was lysed and analyzed by Western blot using
monoclonal anti-HIV gp120 and p24 antibodies.
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confocal microscopy using a fluoresceinated K4-S4 pep-
tide. P4-CCR5 cells treated with fluoresceinated K4-S4
were labeled at their periphery and in the cytoplasm (Fig.
3C). It has been previously observed that DS4 was
localized in erythrocytes cell membrane but not in
cytoplasm (Feder et al., 2000). Here, we show that in
nucleated cells the peptide is also localized in the
cytoplasm. No difference was observed between 1 and
30 min of incubation, indicating that the uptake of the
peptide takes less than 1 min. After washing, the peptide
was not removed and cells remained labeled. When these
cells were submitted to infection by HIV-1LAI, no reduction
of infection was observed (Fig. 3A). Taken together, these
observations suggest that dermaseptin K4-S4 affects
primarily viral particles and inhibits HIV-1 infectivity only
if the peptide in solution is able to bind directly to viral
particles.Dermaseptin K4-S4 disrupts HIV-1 virion integrity
To examine the effect of K4-S4 on the integrity of HIV-1
particles, HIV-1NL43 was treated with either K4-S4 (0.35–35
AM) or 1%NP40 detergent, then concentrated by ultra-
centrifugation. The composition of pelleted HIV-1 particles
after treatment was analyzed by Western blot, using both
anti-gp120 and anti-p24 antibodies. To be able to detect
HIV-1 proteins by Western blot, we used high amounts of
HIV-1NL43 (100 ng p24) in this experiment. Both HIV-1
gp120 envelope protein and the mature p24 Gag protein
were removed from the HIV-1 particles after exposure to
NP40 detergent (Fig. 3D). On the contrary, treatment with
K4-S4 removed only the p24 in a dose-dependent way.
K4-S4 concentrations higher than 3.5 AM depleted most of
p24 Gag protein from particles, suggesting that the peptide
destabilizes the HIV-1 core. HIV-1 envelope glycoprotein
was still present in the pelleted material, even in presence of
Fig. 5. Reduction of HIV-1 attachment to HEC-1 cells and transcytosis of
cell-free HIV-1NDK through a tight HEC-1 epithelial barrier. (A) HEC-1
cells were incubated with a dose range of K4-S4 and 5 ng of virus for 1h30.
Attached-virus was quantified by p24 capture ELISA. Results are shown as
triplicate means F standard deviation. (B) HIV-1NDK (10 ng) was
introduced with serial doses of K4-S4 in the apical chamber of a transwell
system for 24 h. Results of two independent experiments performed in
duplicate are expressed as percentage of virus recovered in the basal
chamber in the presence of K4-S4 compared to the percentage of virus
recovered in the absence of K -S4. Error bars represent standard deviations.
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membrane fragments were recovered by ultra-centrifugation
(Fig. 3D). The activity of dermaseptins is mediated by
interaction of their amphipathic N-terminal domain with
membrane phospholipids (Kustanovich et al., 2002; Mor
and Nicolas, 1994). Our observations suggest that K4-S4
breaks the HIV-1 membrane and destabilizes the core
without melting the lipid bilayer and subsequently reduces
the attachment and/or entry of virus in target cells.
Dermaseptin K4-S4 reduces HIV-1 capture and transcytosis
by epithelial cells and HIV-1 capture and transfer by
MO-DCs
The activity of dermaseptin K4-S4 was then evaluated in
HIV-1 capture and transfer experiments using epithelial
endometrial cells or dendritic cells and primary T lympho-
cytes. Prior to perform these experiments, the cytotoxicity of
dermaseptin K4-S4 was evaluated on these cells. The
viability of human epithelial HEC-1 cells, CD4 T cells
(CEM), human PBL, and monocyte-derived dendritic cells
(MO-DC) was evaluated and compared to that of P4-CCR5
cells after 3 h of exposure to increasing concentrations of
K4-S4 (Fig. 4). Interestingly, HEC-1 endometrial epithelial
cells were less sensitive to K4-S4 than the other cell lines
tested. On the contrary, primary cells (PBL and MO-DC)
were more susceptible than cell lines. For this reason, in all
further experiments on primary cells, K4-S4 was used only
at low non-toxic doses (0.035–350 nM).
To assess the effect of dermaseptin K4-S4 on HIV-1
attachment and transcytosis through a tight epithelial barrier,
we used the human epithelial endometrial cell line HEC-1.
HEC-1 cells were exposed to cell-free HIV-1NDK, HIV-189.6 ,
or HIV-1JR-CSF primary isolates in the presence of increasing
non-toxic concentrations of dermaseptin K4-S4. After
elimination of unattached virus, HIV-1 attachment was
evaluated by quantification of p24 antigen associated toFig. 4. Comparative cytotoxicity of K4-S4 on different cells. Cytotoxicity of
K4-S4 was evaluated using the trypan blue exclusion method after 3 h
exposure of cells to the peptide. Results are means of three independent
experiments F standard deviation.
4the cells. Fig. 5A shows that 35 nM of dermaseptin K4-S4
reduced about 50% of the amount of HIV-1 particles attached
to HEC-1 cells. This inhibition was not dependent on the
viral strain. The reduction of HIV-1 attachment to HEC-1
cells was probably the consequence of the destabilization of
a part of HIV-1 particles by the peptide, and subsequent
reduction the number of intact virions able to attach to cells.
Given the mechanism of action of K4-S4, this peptide is
unlikely to inhibit specifically the interaction between HIV-1
gp120 and cell surface molecules. In this assay, dermaseptin
K4-S4 was active at a concentration 100-fold lower than the
toxic concentration on the same cells, demonstrating that the
peptide is still active at low doses.
To evaluate the capacity of K4-S4 to inhibit HIV-1
transfer through a monostratified epithelium, we used a dual-
chamber system. The apical chamber consisted of a
confluent monolayer of HEC-1 cells, whereas the basal
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on the apical surface of HEC-1 cells together with increasing
doses of dermaseptin K4-S4. The transfer of HIV-1 through
the artificial epithelium was assessed by quantification of
p24 antigen present in the basal chamber after 24 h of
incubation. Fig. 5B shows that transcytosis of cell-free HIV-
1 was inhibited in a dose-dependent way correlating with the
inhibition of attachment to the cells. To control that K4-S4
did not alter the integrity of the epithelial barrier, the
conductivity between apical and basal chambers was
measured before and after peptide incubation. Conductivity
remained constant (200 V/cm2) during all the experiment.
Successful transfer of HIV-1 across epithelial barriers
would result in virus capture by dendritic cells and
subsequent transmission to CD4+ T lymphocytes. Therefore,
we investigated the effect of dermaseptin K4-S4 on HIV-1
capture by monocyte-derived DCs (MO-DCs) and on HIV-1
transmission from MO-DCs to autologous lymphocytes.
MO-DCs were incubated with cell-free HIV-1JR-CSF or HIV-
1NDK in the presence of increasing non-toxic doses of K4-S4.Fig. 6. Reduction of HIV-1 attachment to MO-DCs and MO-DC-mediated infectio
and increasing doses of K4-S4 for 3 h at 37 8C. HIV-1 capture was measured in MO
1 and a dose range of K4-S4 for 3 h. Cells were washed and co-cultivated with au
lymphocytes was evaluated on day 6 of co-culture by p24 capture ELISA in supern
cultivated with MO-DC/HIV-1/K4-S4 compared to virus produced by T cells co cu
HIV-1NDK or HIV-189.6 in presence or absence of K4-S4 and p24 was quantified on
(D) Proliferation capacity of T cells pre-treated with K4-S4 (1 h 30, 0–350 nM). T c
Ag/ml) for 5 days. The results are expressed as stimulation index defined as mean
different donors F standard deviation).After removal of unattached virus, the amount of MO-DC-
attached virus was evaluated by quantification of cell-
associated p24 antigen. Fig. 6A shows that K4-S4 reduced
the amount of HIV-1 particles captured by MO-DCs in a
dose-dependent way (concentrations ranging from 3.5–35
nM induced 50–60% inhibition). The active concentration of
K4-S4 in this assay was 10- to 100-fold lower than toxic
concentration on MO-DCs. Therefore, the peptide is active
on primary cells at low non-toxic concentrations. As in the
case of HEC-1 cells, K4-S4 is unlikely to inhibit specifically
the interaction between gp120 and DC-SIGN but rather
destroys viral particles.
We subsequently investigated the effect of K4-S4 on
HIV-1 transmission from MO-DCs to autologous lympho-
cytes. MO-DCs were incubated with HIV-1NDK or HIV-1JR-
CSF in the presence of increasing non-toxic doses of K4-S4.
After removal of free viral particles, autologous lympho-
cytes were added to the infected MO-DCs and co-cultivated
for 6 days. HIV-1 production was assessed in co-cultures
supernatants. Fig. 6B shows that K4-S4 reduced the trans-n of autologous T cells. (A) MO-DCs were incubated with 20 ng/ml HIV-1
-DCs by p24 capture ELISA. (B) MO-DCs were incubated with 0.5 ng HIV-
tologous stimulated T cells (DC–T cell ratio 1:5). The viral production by T
atants. The data are expressed as percentage of virus produced by T cells co
ltivated with MO-DC/HIV-1. (C) Primary T lymphocytes were infected by
day 6. All results are presented as mean of triplicate F standard deviation.
ells were stimulated with IL2, PHA/IL2, or MO-DCs in presence of PDT (5
cpm of stimulated samples/mean cpm of unstimulated samples (mean of 2
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lymphocytes in a concentration-dependent way. This inhib-
ition was not dependent on the viral strain. This inhibition is
likely due to the reduction of HIV-1 particles captured by
MO-DCs. Lastly, we investigated the effect of dermaseptin
K4-S4 on cell-free HIV-1 infection of PBLs. At the same
concentration reducing HIV-1 attachment to epithelial cells
and MO-DCs, K4-S4 reduced similarly T lymphocytes
infection by HIV-1 (Fig. 6C).
K4-S4 could have an immunosuppressive effect on T
lymphocytes or MO-DCs, which could not be detected by
the trypan blue exclusion method. Thus, we evaluated the
proliferative capacity of these cells in presence of increasing
doses of K4-S4 (0–350 nM). Fig. 6D shows that CD3
+ T
lymphocytes proliferation after specific stimulation by
autologous MO-DCs of after non-specific stimulation by
PHA and/or IL-2 was not significantly affected by K4-S4.Discussion
These experiments show that dermaseptin K4-S4 inhibits
the infectivity of primary and laboratory-adapted strains of
HIV-1 and CCR5- or CXCR4-mediated infection. This pep-
tide reduces partly HIV-1 attachment to human endometrial
cells (HEC-1) and HIV-1 transcytosis through a tight HEC-1
monolayer. Similarly, HIV-1 attachment to MO-DCs and
subsequentMO-DC-mediated infection of autologous T lym-
phocytes are reduced. HIV-1 infection is inhibited when
dermaseptin K4-S4 is present during virus-cell contact, but no
reduction is observed when it is added after, suggesting that
the antimicrobial peptide targets HIV-1 before entry. These
experiments also show that K4-S4 exerts a selective activity
on viral particles and disturbs their organization by breaking
the viralmembrane, leading to the exposure ofHIV-1 core and
its dissociation. This bvirucideQ activity, which is non-specific
of any type of HIV-1 and independent of host cells, results in a
rapid loss of infectivity of HIV-1 before virus-cell contact.
When used at high concentrations, this natural antimi-
crobial peptide is cytotoxic in vitro for host cells. However,
modifications can be achieved on the native sequence to
reduce its toxicity without altering activity. To increase the
selectivity index of DS4 for HIV-1, we tested for deletions
and substitutions, based on previous studies performed with
Escherichia coli and human red blood cells (Feder et al.,
2000). Our results show that a positive charge substitution
leads to a lower cytotoxicity of the peptide without altering
its anti-HIV-1 activity. The derived peptide K4-S4 appears to
be the best candidate in these assays. The selective activity
of antimicrobial dermaseptins depends on the membrane
lipid composition of the microbe versus the host cell and its
electrical potential (Diaz-Achirica et al., 1998). For exam-
ple, although the lipid compositions of host cell and P.
falciparum membrane are similar, the potential of the
parasite membrane is higher than that of the host cell
membrane, leading to a discriminating effect of DS4 (Efronet al., 2002). We observed that primary cells were more
sensitive to the toxic effect of K4-S4 than cell lines.
However, the peptide was able to reduce 50% of HIV-1
infection on primary CD4+ T cells at a concentration (35
nM) 10- to 100-fold lower than the toxic concentration on
these cells. The discrepancy that we observed between the
active doses of K4-S4 against HIV-1 infectivity on P4-CCR5
cells and primary CD4+ T cells could be explained by the
higher susceptibility of P4-CCR5 cells to HIV-1 infection.
For sexual transmission to occur, HIV-1 must first cross
the mucosal epithelium (Shattock and Moore, 2003). We
used an in vitro model mimicking the penetration of HIV-1
through unstratified epithelium by using a polarized mono-
layer of endometrial epithelial cells (HEC-1). We observed
that 35 nM of dermaseptin K4-S4 inhibit about 50% of both
HIV-1 attachment on HEC-1 and transcytosis through the
tight epithelial barrier. This K4-S4 concentration was 100-
fold lower than the toxic concentration on HEC-1 cells.
Interestingly, human endometrial epithelial cells are less
sensitive to the toxic effect of K4-S4 than other cells. This is
an important point because these cells would be the major
cell population in contact with a topical anti-HIV-1 micro-
bicide. After passage across the epithelium, HIV-1 particles
are captured by migratory dendritic cells (mediated by DC-
SIGN or another mannose C-type lectin receptor) or infect
susceptible cells (DCs, T cells, macrophages) (Pope and
Haase, 2003; Shattock and Moore, 2003). HIV-1-carrying
DCs can disseminate infectious virions to draining lymph
nodes, where massive infection of CD4+ T cells takes place
(Geijtenbeek et al., 2000; Masurier et al., 1998). Blocking
HIV-1 uptake by DCs and subsequent transmission to CD4+
T cells is crucial for the prevention of HIV-1 sexual
transmission. We observed that dermaseptin K4-S4 reduces
MO-DC-mediated viral transmission to autologous T cells
by reducing the number of HIV-1 virions able to attach to
MO-DCs, at concentrations (3.5–35 nM) that are 10- to 100-
fold lower than the toxic concentration on these primary
cells. As a control for toxicity, we show that these active
doses do not inhibit antigen-presentation by DCs and do not
alter activation of T lymphocytes. However, these non-toxic
concentrations of K4-S4 prevent only 50% of HIV-1 capture
by MO-DCs and subsequent infection of primary CD4+ T
cells. To reach 90–100% reduction, a further modified
derivative of dermaseptin with lower toxicity for host cells
could be used at higher concentrations. Low non-toxic doses
of dermaseptin K4-S4 might be also tested in combination
with other anti-HIV entry inhibitors or further modified to
reduce its toxicity.
The cytotoxicity for host primary cells of a non-specific
anti-HIV-1 compound is an important issue. Indeed, the
nonoxynol-9, a non-specific surfactant, which destroys HIV-
1 particles in vitro (Polsky et al., 1988), caused lesions in
the vaginal epithelium in vivo and increased the probability
of being infected with HIV-1 (Van Damme et al., 2002). Our
observations show that dermaseptin K4-S4 does not behave
as a detergent since viral membrane structures are preserved.
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membranes, which may enable the passage of low molecular
weight molecules leading to the membrane lysis (Shai,
1999). The in vivo toxicity of dermaseptin K4-S4 has to be
studied to determine if this peptide could disrupt the
epithelial barrier at low doses. Macaque challenge experi-
ments with other microbicides in development predict that
doses 1000 times higher than that active in vitro are required
to provide protection in vivo (Lederman et al., 2004). The
mucosal physiological conditions (pH, mucus viscosity) will
influence the stability, toxicity, and activity of biologically
active peptides. The antibacterial activity of dermaseptin
K4-S4 has been shown to be maintained a low pH
conditions, suggesting that the peptide could be active in
genital tract (Yaron et al., 2003). Whether the in vivo active
versus toxic doses of dermaseptin K4-S4 will remain similar
to that observed in vitro has to be determined. Although
dermaseptin K4S4 has an improved toxicity profile, further
perfection is desirable to reach the safety of an acceptable
microbicide. One of the derivative evaluated in this study,
the K4S4(1–16)a analog, inhibited 50% of HIV-1 infection
on P4-CCR5 cells with a concentration of 28 AM. This
analog was less active than K4-S4 but did not cause cell
toxicity with concentrations up to 100 AM. The K4S4(1–
16)a derivative has proved antibacterial activity in vivo with
no toxicity associated in mice which received a systemic
injection of 250 Ag (11 mg/kg) (Navon-Venezia et al.,
2002). Such a shorter derivative with lower activity but
lower toxicity should be evaluated in vivo.
Sexually transmitted diseases (STDs) that cause ulcers
and epithelial inflammation greatly increase the efficiency of
HIV-1 transmission by increasing both the infectiousness of
HIV-1 and the susceptibility to HIV-1 infection (Galvin and
Cohen, 2004). Ideally, topical microbicides should be
inexpensive, easy to use, and stable under low pH condition,
non-irritating to genital mucosal tissues, and have a broad
spectrum of activity against a variety of sexually transmitted
microbes within genital secretions and against HIV-1.
Dermaseptin S4 is active against a large spectrum of bacteria,
parasites, HSV-1, and in our study, against HIV-1 at non-
toxic doses in vitro. Its activity could be evaluated against
other STDs (HSV-2, Trichomonas vaginalis, Tepanema
pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis,
Candida albicans, Gardnerella, Mobiluncus, Mycoplasma,
Ureaplasma, etc). Other compounds are active against both
HIV-1 and HSV-2 (Bourne et al., 1999; Gyotoku et al., 1999;
Herold et al., 2002; Zacharopoulos and Phillips, 1997).
These compounds might reduce HIV-1 infection both
directly and indirectly by reducing other STDs.
A number of potential microbicides are under develop-
ment (Golding et al., 2003; O’Hara and Olson, 2002; Shat-
tock andMoore, 2003; Stone, 2002;Wang et al., 2003). Some
of them have been suggested to interact directly with gp120
or gp41 of HIV-1, such as polianions (dextran sulfate, PRO-
2000, carageenan), T-20, Cyanovirin, Retrocyclin, mAb b12,
or mAb 2F5. Others target CD4 or co-receptors, such as anti-CD4 mAbs, anti-CCR5 mAbs, PSC-RANTES, AMD3100,
or anti-CCR5 peptides. These specific blocking molecules
would subject the virus to selective pressure andmight lead to
the emergence of resistant strains (Moore and Doms, 2003).
Using in combination molecules that target several steps in
HIV-1 transmission could prevent drug resistance (Stone,
2002). Dermaseptin K4-S4 prevents HIV-1 infection by
disrupting HIV-1 particles without specific interactions with
HIV-1 proteins or receptors. Thus, resistance to this peptide
should not occur. Therefore, dermaseptin K4-S4 deserves to
be further evaluated in animal models to test its toxicity in
mucosal tissues and its ability to block HIV-1 sexual
transmission alone or in combination with other potential
compounds.Methods
Synthesis of peptides
Peptides were synthesized by the solid- phase method the
f-moc (9-fluorenylmethyloxycarbonyl) active ester chemis-
try on a fully automated, programmable Pioneer Peptide
Synthesis System (Applied Biosystems). Preloaded PAC-
PEG-PS-resin and PAL-PEG-PS-resin were used to obtain
free carboxyl and amidated peptide, respectively. Side chain
protections were tert-butylcarboxyl for lysine and trypto-
phan, o-tert-butyl ether threonine, and trityl for asparagine.
Cleavage of the peptidyl resins and side chain deprotection
were carried out in trifluoroacetic acid (TFA), triethylsilane
(TIS), and water (95:2.5:2.5 v/v/v) mixture (10 ml/g of
peptidyl resin) for 2 h at room temperature. After filtration of
the resin, the peptide-TFA filtrate was precipitated in ice-
cold diethyl ether, then dissolved in 0.08% TFA and
lyophilized. The crude peptide was purified to chromato-
graphic homogeneity by reverse-phase high performance
liquid chromatography (HPLC). HPLC runs were performed
on preparative C18 columns with a linear gradient of
acetonitrile in water (1%/min); both solvents contained
0.08% TFA. To confirm their composition, the purified
peptides were subjected to amino acid analysis and mass
spectrometry. Peptides were stored as lyophilized powder at
20 8C. Prior to experimentation, fresh solutions were
prepared in water and diluted in the appropriate medium. For
fluorescein-labeled peptides, fluorescein was introduced at
the N-terminus of the peptide using fluorescein N-hydrox-
ysuccinimide ester prior to TFA treatment.
Cells lines and virus strains
P4-CCR5 indicator cells (Hela-CD4-CXCR4-CCR5-
HIVLTR-LacZ) express the CD4, CXCR4, and CCR5 HIV-
1 receptors and have been stably transfected with lacZ under
transcriptional control of the HIV-1 long terminal repeat
(LTR) (Charneau et al., 1994). P4-CCR5 and CEM cells were
maintained in Dulbecco’s modified Eagle’s medium
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ml G418. Epithelial cell line HEC-1 was maintained in RPMI
1640 containing 10% FCS and antibiotics.
Different HIV-1 isolates were used: the laboratory
adapted strain X4-tropic LAI, NL43, clade B R5/X4-tropic
primary isolates Bx08 (C. Moog, INSERM, Strasbourg,
France) and 89.6 (F. Barre´-Sinoussi, Institut Pasteur, Paris,
France), clade B R5-tropic primary isolates 92US660,
92US714, 92HT593, JR-CSF (NIH-AIDS Research and
Reference Reagent Program), clade B X4-tropic primary
isolate NDK (F. Barre´-Sinoussi, Institut Pasteur, Paris,
France), and a clade A R5-tropic primary isolate 3253 (G.
Pancino, Institut Pasteur, Paris). These viruses were
propagated on PBL from healthy donors stimulated with
phytohemagglutinin (PHA) and interleukin-2 (IL-2) and
quantified in cell culture supernatants by HIV-p24 ELISA
(HIV-1 core profile ELISA, DuPont de Nemours, France).
Primary R5-tropic HIV-1JR-CSF was amplified in monocyte-
derived macrophages from healthy donors.
T lymphocytes and MO-DCs preparation
Human dendritic cells (DCs) were generated from mono-
cytes. Peripheral blood mononuclear cells (PBMC) were
isolated from heparinized buffy coats of healthy adult
donors by Ficoll density gradient centrifugation (MSL,
Eurobio, France). PBMC were resuspended in RPMI 1640
medium supplemented with glutamine, penicillin (100 IU/
ml), and streptomycin (100 Ag/ml). Cells were seeded into
24-well plates (1  106 adherent cells/ml) and incubated at
37 8C for 45 min. Non-adherent cells were removed by four
washes. Adherent monocytes were incubated in RPMI
medium with 10% fetal calf serum (FCS), glutamine, and
antibiotics in the presence of 10 ng/ml rhIL-4 and 10 ng/ml
rhGM-CSF. Half the medium was replaced every 2 days.
After 6 days of culture, non-adherent cells corresponding to
the DC-enriched fraction were harvested, washed, and used
for subsequent experiments. Flow cytometry analysis using
forward scatter and side scatter properties (Becton Dick-
inson) demonstrated that the DCs were more than 90% pure.
T cells were prepared from the monocyte-depleted cell
fraction. The negatively selected T cells were collected and
more than 98% expressed CD3 by flow cytometry analysis.
Peripheral blood lymphocytes (PBLs) were cultured for 48 h
in fresh medium supplemented with PHA (2.5 Ag/ml) and
IL-2 (1 Ag/ml). PBLs were then washed and cultured in
growth medium containing IL-2 (1 Ag/ml) for 24 h.
Antiviral activity assays on P4-CCR5 cells
P4-CCR5 cells were seeded in 96-well plates (20,000
cells per well) and incubated at 37 8C in DMEM, 10% FCS
for 24 h. Infections were performed by replacing the medium
by 50 Al DMEM, 10% FCS, DEAE dextran (10 Ag/ml)
containing HIV-1 virus (1 ng p24) and increasing DS4
concentrations. Cells were infected for 2 h at 37 8C withHIV-1LAI and 24 h with primary isolates. After washing to
remove the unattached virus and the peptide, cells were
incubated at 37 8C. After 2 days, the h-galactosidase activity
was measured using a Chemiluminescence Reporter Gene
Assay (Roche, USA). To examine whether K4-S4 interacts
primarily with HIV-1 or cells, the peptide (3.5 AM) was pre-
incubated at 37 8C with cell-free HIV-1LAI. The remaining
viral infectivity was then assessed over time on P4-CCR5
cells. Alternatively, DS4 (or DMEM 10% FCS as control)
was pre-incubated with cells for 1 h at 37 8C and cells were
washed prior to infection with HIV-1LAI.
Cytotoxicity assays
The cytotoxicity of dermaseptin was evaluated on P4-
CCR5, HEC-1, PBLs, and monocytes-derived dendritic
cells (MO-DCs) by quantifying cell viability using the
trypan blue-exclusion method following 3–24 h exposure to
increasing concentrations of DS4 or K4-S4 derivative. More
sensitive assays were also used to evaluate K4-S4 cell
toxicity: the immune functions of MO-DCs and T lympho-
cytes were evaluated using proliferation assays after treat-
ment with K4-S4. Bulk CD3
+ T cells from healthy donors
were incubated for 1 h 30 with K4-S4 increasing concen-
trations in 96-well plates (105 cells per well, in RPMI 1640,
10% FCS). Cells were then stimulated with PHA, IL-2, or
MO-DCs in presence of purified derivative of tuberculin
(PDT) (5 Ag/ml) for 5 days in 5% CO2 at 37 8C. All assays
were performed in triplicate. Cells were pulsed with 0.5 ACi/
well (Saphire et al., 2001) thymidine 18 h before the end of
incubation then harvested using an automatic collector (EG
and G Wallc, Turku, Finland). Isotope incorporation was
measured with a Microbeta Liquid Scintillation Counter
(EG and G Wallc, Turku, Finland) and stimulation index
was determined as the ratio between mean cpm in
stimulated samples and mean cpm in control samples.
Cellular localization of fluorescent peptide by microscopy
P4-CCR5 cells were incubated in presence of the
fluoresceinated peptide K4-S4 at 1–10 AM. After 1–30 min
incubation, cells were washed and analyzed (non-fixed
cells). Microscope images were taken using a Zeiss axioplan
2 imaging microscope with Apotom system.
HIV-1 virion isolation and immunoblotting
HIV-1NL43 (100 ng p24) was incubated alone or in
presence of increasing concentrations of K4-S4 (0.35–35
AM) at 37 8C for10 min. The same amount of virus was
incubated with NP40 detergent (1%) at 4 8C for 30 min.
Samples were then ultra-centrifuged at 30,000 rpm through
5-ml PBS at 4 8C for 1 h 30. Pelleted material was
resuspended in 50 Al of 150 mM NaCl, 50 mM Tris, pH 8,
1% NP40, 0.5 mM PMSF, and 0.2 mg/ml Pefabloc
(Interbiotech, France). Proteins were denatured by treatment
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separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (4–12% NuPage, Invitrogen). After transfer
to cellulose membrane (Amersham Pharmacia Biotech),
blots were probed with a mouse monoclonal anti-HIV p24
antibody (23A5G4) or with mix of mouse monoclonal
anti-HIV gp160 and gp120 antibodies (110H, 160A, O.
Schwartz, Institut Pasteur, France). A goat anti-mouse IgG
horseradish peroxidase (HRP) conjugate (Amersham) was
used as a secondary antibody. Peroxidase activity was
visualized with an enhanced chemiluminescence detection
Kit (ECL+, Pierce).
HIV-1 attachment on epithelial cells and transcytosis
Human epithelial endometrial cells (HEC-1 cell line)
were incubated in 48-well plates with HIV-1 (5 ng p24) and
increasing doses of dermaseptin K4-S4. Each sample was
performed in triplicate. After 1 h 30 min of incubation,
unattached virus was removed (4 washes) and cells were
lysed (1% Triton X-100 for 45 min at 37 8C). Cell lysates
were harvested and centrifuged at 1800 rpm for 5 min. The
amount of HIV-1 p24 associated to cell lysates was
evaluated using HIV-p24 ELISA (HIV-1 core profile
ELISA, DuPont de Nemours, France). To analyze HIV-1-
free particles transcytosis through an epithelial monostrati-
fied barrier, HEC-1 cells were grown as a tight polarized
monolayer on a permeable polycarbonate support (0.4-Am
pore-diameter, Transwell, Costar, Cambridge, MA) as
previously described (Bomsel et al., 1998; Hocini et al.,
2001). The tightness of the monolayer of HEC-1 cells was
monitored by controlling that resistivity remained above
200 V/cm2 in presence of K4-S4. HIV-1 (10 ng p24) was
added on the apical pole of the HEC-1 monolayer together
with increasing doses of dermaseptin K4-S4 and cells were
incubated for 24 h at 37 8C. HIV-1 transcytosis was assessed
by detecting the presence of p24 antigen in the basolateral
chamber of the transwell. The inhibition of transcytosis was
expressed as the percentage of p24 antigen recovered in the
basolateral chamber in the presence of dermaseptin K4-S4
by comparison to that recovered without peptide.
HIV-1 attachment on human dendritic cells and
DC-mediated infection of autologous T cells
After 6 days of differentiation, human DCs were washed
three times and seeded into 96-well culture plates (5  105
cells/well). HIV-1 (20 ng p24) together with increasing
doses of dermaseptin K4-S4 were added on cells and
incubated for 3 h at 37 8C. Each sample was performed in
triplicate. After four washes to remove the unattached virus,
cells were lysed by incubation for 45 min at 37 8C with 1%
Triton X-100. Cell lysates were harvested and centrifuged at
1800 rpm for 5 min. The amount of cell-associated HIV-1
was evaluated using HIV-1 p24 ELISA (HIV-1 core profile
ELISA, DuPont de Nemours, France). To assess thetransmission of HIV-1 from dendritic cells to autologous T
cells, DCs were incubated into 96-well culture plates (5 
105 cells/well) and infected with HIV-1 (0.5 ng p24) in the
presence of increasing doses of dermaseptin K4-S4 for 3 h at
37 8C in a 5% CO2 atmosphere. Cells were washed four
times and autologous stimulated T cells were added onto
infected DCs at a DC–T-cell ratio of 1:5. Each sample was
performed in triplicate. Culture supernatants were harvested
every 3 days and fresh medium was added. Supernatants
were inactivated with 1% Triton X-100 and frozen at 20
8C. The viral production by T lymphocytes was evaluated
after 6 days of culture by measurement of p24 in super-
natants using capture ELISA.Acknowledgments
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